# E130: Telitacicept for SLE

Page: https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e130-telitacicept-for-sle
Text version: https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e130-telitacicept-for-sle.md
Podcast: [The Evidence Based Rheumatology Podcast](https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175)
Published: 2025-12-22T23:07:00+00:00
Episode link: https://msputman.podbean.com/e/e130-telitacicept-for-sle/
Audio file: https://mcdn.podbean.com/mf/web/vgu8xxnmt9ztaztd/e130.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e130-telitacicept-for-sle
Duration seconds: 786

## Resource

Surprisingly (unbelievably?) impressive RCT evaluating the Blys/APRIL inhibitor "telitacicept" for patients with SLE (mixed SLE and SLE-LN). Very curious to see where the FDA goes with this one. Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2414719

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e130-telitacicept-for-sle/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e130-telitacicept-for-sle.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.